

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial

Wenhui Zhang, PhD,^{*||} Astrid Scalori, MD,^{†,||} Franklin Fuh, BS,^{*} Jacqueline McBride, PhD,^{*} Gaohong She, MS,^{*} Jaroslaw Kierkus, MD, PhD,[‡] Bartosz Korczowski, MD, PhD,[§] Regan Li, MSc,[†] Mariam Abouhossein, PharmD, RPh,^{*} Alysha Kadva, PhD, MA,^{*,||} K. T. Park, MD,^{*} and Meina Tao Tang, PhD^{*,||}

From the *Genentech, Inc., South San Francisco, CA, USA

[†]Roche Products Limited, Welwyn Garden City, United Kingdom

[‡]Children's Memorial Health Institute, Warsaw, Poland

[§]University of Rzeszów, Rzeszów, Poland

^{*}W. Zhang and A. Scalori contributed equally to this manuscript.

^{||}Affiliation at time of study.

Address correspondence to: Wenhui Zhang, PhD, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA (zhang.wenhui@gene.com).

In the originally published version of this manuscript, there was an error in the seventh author's name. The seventh

author's name should read: "Bartosz Korczowski" instead of "Bartosz Korczowksi". This error has been corrected.